In addition to exploring combination strategies with classical immune checkpoints (PD-1, PD-L1, CTLA4), an alternative approach is to validate additional checkpoints as potential therapeutic targets in prostate cancer. This evidence concerns the gene CD274 and prostate carcinoma.